Uncategorized
Clearside, Santen expand collaboration into glaucoma research
Clearside Biomedical and Santen, having worked together since January 2013 to develop drugs to treat retinal and choroidal diseases, announced plans to expand their collaborative relationship into glaucoma research.The expanded collaboration will focus on use of Clearside’s proprietary microinjector to deliver sustained-release formulations of IOP-lowering drugs via the suprachoroidal space, according to a joint press release from the companies.